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Abstract
Infection with drug-resistant human immunodeficiency virus type 1 (HIV-1) has been documented in all
countries that have surveyed for it and may result in an unfavorable response to therapy. The prevalence and
characteristics of individuals with transmitted resistance to antiretroviral drugs have been scarcely described in
Brazil. We performed antiretroviral resistance testing prior to initiation of therapy in 400 subjects enrolled from
20 centers in 13 Brazilian cities between March and September 2007. Genotyping was conducted using PCR-
amplified HIV pol products by automated sequencing, and genotype interpretation was done according to the
IAS-USA consensus. Of 400 eligible participants, 387 (95.8%) were successfully tested. Seven percent of anti-
retroviral-naive patients carried viruses with one or more major mutation associated with drug resistance. The
prevalence of these mutations was 1.0% for protease inhibitors, 4.4% for nonnucleoside reverse transcriptase
inhibitors, and 1.3% for nucleoside reverse transcriptase inhibitors. The frequency of multidrug resistance among
the resistant strains was 13.6%. Among subjects infected with drug-resistant virus, the majority were infected
with subtype B viruses (91%). Subjects from the city of São Paulo had higher transmitted resistance mutations
compared to the rest of the country. Reporting a partner taking antiretroviral medications was associated with a
higher chance of harboring HIV variants with major drug resistance mutations [odds ratio¼ 2.57 (95% confi-
dence interval, 1.07–6.16); p¼ 0.014].
Resistance testing in drug-naive individuals identified 7% of subjects with mutations associated with reduced
susceptibility to antiretroviral drugs. Continued surveillance of drug-resistant HIV-1 in Brazil is warranted when
guidelines for HIV prophylaxis and treatment are updated. Resistance testing among drug-naive patients prior
to treatment initiation should be considered, mainly directed at subjects whose partners are already on anti-
retroviral therapy.
Introduction
The introduction of highly active antiretroviral therapy(HAART) in patients infected with human immunodefi-
ciency virus type 1 (HIV) is associated with a marked reduc-
tion in morbidity and mortality1–3 and a significant recovery
of the compromised immune function.4,5 Resistance to anti-
retroviral (ARV) drugs is a major cause of treatment failure
in individuals with HIV infection and has been associated
with higher mortality rates.6–9 The prevalence of ARV drug-
resistant virus has been reported to vary between 1% and 18%
in newly infected HIV persons in North America.10–14 While
some authors did not find a significant trend in prevalence of
transmitted resistance mutations over years,15 others have
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reported an increasing proportion of new infections that in-
volve drug-resistant virus in Europe.16 Moreover, the time to
viral suppression might be longer and the time to virologic
failure shorter among patients who are infected with drug-
resistant viruses who start HAART.17
The transmission of virus with mutations that confer re-
sistance to ARV drugs has been reported with all main routes
of transmission.18–24 Increasing rates of resistance may not
only limit future therapeutic options, but also affect HAART
efficacy, even under postexposure prophylaxis.25,26 Thus, re-
sistance testing before initiation of therapy may be of value in
selected sites to help determine the most appropriate ARV
combination regimen. More than a decade ago, Brazil was the
first nation to offer universal and free access to ARV drugs to
HIV-positive persons. Nevertheless, there are scant data about
transmission of resistant virus to individuals who were sup-
posed not to have been exposed to antiretroviral drugs.27,28 In
the current study, we evaluated the prevalence of transmitted
HIV mutations in a cohort of drug-naive, HIV-infected sub-
jects from different regions of the country.
Materials and Methods
Study subjects
HIV-seropositive patients were enrolled from 20 sites in
13 Brazilian cities (Ribeirão Preto, Santo André, Santos,
Nova Iguaçu, Rio de Janeiro, Belo Horizonte, Curitiba,
Florianópolis, Salvador, Brası́lia, 2 in Campinas, 2 in Porto
Alegre, and 6 in São Paulo City) between March and Sep-
tember 2007. This selection comprised eight states from four
of the five major macroregions in Brazil, but for the sake of
comparison we have grouped cities according to their rele-
vance for the Brazilian AIDS epidemic. Therefore, subjects
were grouped geographically as from São Paulo City, São
Paulo State (Ribeirão Preto, Santo André, and Campinas),
Santos (which has reported the highest primary resistance in
the country),29 Southern Brazil (Curitiba, Florianópolis, and
Porto Alegre), and others (all remaining cities). Eligibility
criteria included age 18 years and no previous exposure to
ARV drugs before the time of sampling according to the
medical chart review (if a chart was available) and personal
interview. After informed consent was obtained, demo-
graphic, risk behavior, and clinical information was obtained
using standardized interviews. Results from CD4þ T lym-
phocyte count and plasma HIV RNA levels, measured within
the previous 3 months of enrollment, were also obtained from
medical charts. Blood specimens for drug resistance testing
were obtained from each consenting participant. The study
was approved by the institutional review boards affiliated
with the centers in which participants were recruited.
Resistance testing
Protease (PR) and reverse transcriptase (RT) genotyping
was conducted on the basis of HIV PCR-amplified products
with the ViroSeq system (Celera, Rockville, MD) according to
the manufacturers’ specifications. Briefly, viral RNA was
isolated from plasma of HIV-positive enrolled individuals
and subject to RT-PCR to amplify a 1.7-kb viral genomic
fragment corresponding to the whole coding region of HIV
PR and the first 335 codons of RT, which comprises all posi-
tions associated with drug resistance.30 PCR products were
further sequenced using the BigDye termination chemistry
(Applied Biosystems, Foster City, CA) with seven primers
provided with the ViroSeq kit. DNA sequencing was per-
formed in an ABI Prism Genetic Analyzer DNA (Applied
Biosystems) and sequence reads were automatically assem-
bled in the Viroseq software, which also interpreted genotypic
resistance and HIV-1 viral subtype in an automated fashion.
Genotypic resistance was defined as the presence of one or
more resistance-related major mutation as specified by the
consensus of the International AIDS Society (IAS; Spring 2008
version).31
Statistical analyses
Patients were grouped into those presenting primary drug
resistance and those who did not. Demographic characteris-
tics and clinical, laboratory, and molecular (HIV subtype)
data were compared between those groups and statistically
significant differences were assessed by Fisher’s exact test of
contingency tables.
The odds ratio (OR) and corresponding 95% confidence
interval (CI) for transmitted drug-resistant HIV were calcu-
lated for those characteristics that were significantly different
between the abovementioned groups. All statistical analyses
were performed using Statistica software version 5.1=97.
Results
Study population
Four hundred and one patients were enrolled (20 per cen-
ter, with the exception of one center that enrolled 21 patients).
One patient was excluded from the analyses due to a protocol
violation, having had previous exposure to ARV therapy. One
patient under 18 years of age, considered as a protocol devi-
ation, was analyzed after informed consent was obtained
from a legally authorized representative. Table 1 summarizes
the demographic and clinical characteristics of the study
population. The majority of patients (69%) were white, and
two-thirds were male. Forty-three percent of the patients were
men who reported sex with other men (MSM), 2.5% were
intravenous drug users (IDU), and 54% were heterosexual
and=or had other risk factors for HIV acquisition. At baseline,
the median CD4þ T cell lymphocyte count was 375 cells=ml
[interquartile (IQR) range, 2–2455], and 5.4% of patients had a
CD4 count lower than 50 cells=ml. Viral load information was
available for 76.5% of the patients, and the median HIV RNA
level was 24,896 copies=ml (IQR range, 184–941,910).
Drug resistance analysis
Three hundred and eighty-seven (96%) subjects underwent
drug resistance testing. For the remaining subjects, resistance
analysis was not possible due to lack of PCR amplification for
genotyping. Twenty-two of 387 (5.7%; 95% CI, 4.4–9.6%)
ARV-naive subjects carried viruses with one or more major
resistance-related mutation. The prevalence of resistant geno-
types varied according to the drug class: 1% (4=387) for pro-
tease inhibitors (PI), 4.4% (17=387) for nonnucleoside reverse
transcriptase inhibitors (NNRTIs), and 1.3% (5=387) for nu-
cleoside=nucleotide reverse transcriptase inhibitors (NRTIs).
Table 2 shows the primary protease and RT mutations found
in all isolates with resistance mutations in the study popula-
tion. Of the 22 subjects with resistance-related mutations,
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19 (87%) had mutations associated with only one drug class, 2
(9%) with two drug classes, and 1 (4%) with all three drug
classes. Other mutations recently listed as transmitted drug
resistance related,32 but which are not considered as resistance
mutations according to the IAS-USA list, were also observed.
That was the case of mutations T215S (found in viruses from
three subjects), T215D (two viruses), and T69D (three viruses).
Five of these mutations were found in viruses with other
drug-related mutations, while three (two T215S and one
T69D) were found alone (Table 2).
The rate of transmission of drug resistance in each region
varied from 0% (0=18) in the city of Santos to 9.9% (13=118) in
the city of São Paulo. Indeed, we found a trend of association
between higher transmitted resistance and individuals from
São Paulo City ( p¼ 0.038; Table 1). Although 66% of the total
subjects were infected with subtype B viruses, the pro-
portion in the 22 subjects with drug resistance was 91%,
suggesting higher transmitted resistance among subtype B-
infected patients ( p¼ 0.03). Finally, in the 304 subjects for
whom such information was available, reporting a partner
taking ARV medications was associated with a higher chance
of harboring resistant HIV variants (OR¼ 2.57; 95% CI, 1.07-
6.16; p¼ 0.014).
Discussion
Currently, resistance testing is recommended at the time of
diagnosis of HIV infection in the United States as part of the
initial comprehensive patient assessment, as well as in all
cases of virologic failure settings as a guide to the optimal









Male 265 (66.3%) 16 (72.7%)
Female 135 (33.8%) 6 (27.3%)
Race=ethnicity
White 276 (69.0%) 17 (77.3%)
Black 68 (17.0%) 2 (9.1%)
Mixed race 54 (13.5%) 3 (13.6%)
Asian 1 (0.3%) 0 (0%)
Native Brazilian 1 (0.3%) 0 (0%)
Geographic region
São Paulo (capital) 140 (35.0%) 13 (59.1%) 0.038
São Paulo State 60 (15.0%) 2 (9.1%)
Santos 20 (5.0%) 0 (0%)
Southern Brazil 80 (20.0%) 5 (22.7%)
Others 100 (25.0%) 2 (9.1%)
HIV risk behavior
Male-to-male sex 173 (43.2%) 9 (40.9%)
Injection drug useb 10 (2.5%) 0 (0%)
Heterosexual exposure=otherb 217 (54.3%) 13 (59.1%)
Time of infection in years
Median 1 2
Interquartile range 0–18.0 0–8
CD4þ count (cells=ml)
Median 375 449
Interquartile range 2–2,445 50–869
HIV RNA level (copies=ml)
Median 24,896 19,825
Interquartile range 184–941,910 7,110–27,400
HIV subtypec
B 264 (66.0%) 20 (91%) 0.03
C 51 (12.8%) 1 (4.5%)
Non-B non-C 68 (17.0%) 1 (4.5%)
Not available 17 (4.3%) —
Partner taking HIV medications
Yes 92 (23.0%) 10 (45.5%) 0.014
No 226 (56.5%) 7 (31.8%)
Unaware 82 (20.5%) 5 (22.7%)
aOnly significant p-values ( 0.05) are shown.
bDoes not include individuals who also reported male-to-male sex.
cHIV subtype prevalence refers to 387 patients, for which HIV molecular data (subtype and drug resistance) could be obtained.
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choice of treatment strategies.33 However, especially in de-
veloping countries, cost issues weigh heavily on the im-
plementation of the test for drug-naive patients. Therefore,
knowing the local prevalence and the pattern of resistance-
related mutations has obvious implications on a discussion
about performing resistance testing prior to initiation of
therapy. The results of this study, carried out in 20 health care
centers in Brazil, showed that 5.7% of HIV-1-infected subjects
who had never received antiretroviral therapy carried viruses
with one or more resistance-related mutation. This is in
agreement with another nationwide study conducted in Bra-
zil in 2002, in which a rate of 6.6% was found.28 Our study,
however, involved a larger number of genotyped viruses and
a larger geographic coverage of the Brazilian territory. When
considering the most recent list of transmitted drug resistance
markers,32 the proportion virtually did not change, because
all but one virus carried additional, established drug resis-
tance mutations. This indicates that current estimates of drug
resistance are still valid for epidemiologic assessments, at
least in our scenario. A rate of 5.7% can still be considered a
modest estimate when compared to those of developed
nations, where rates of 9–16% have been reported.34–40
However, recent reports from Europe have pinpointed a sta-
bilization of or a decrease in the rates of drug resistance,41,42
indicating rates similar to or even lower that those found
herein, suggesting that Brazil is reaching a primary drug re-
sistance profile of developed settings.
Although we tried to cover most of the important regions of
the country and this was precisely the reason we included as
many individuals as our budget permitted, our study has
some weaknesses. Our population had a median count of 375
CD4þ lymphocytes, reflecting a more chronic course of dis-
ease than the scenario of some years ago, when these indi-
viduals likely acquired HIV. We also were expecting a higher
presence of resistance mutations in the city of Santos, in São
Paulo state, as previously reported.29 However, we were not
able to detect such a profile. This fact might have reflected
‘‘microdifferences’’ that could occur in the same region, indi-
cating that HIV-positive individuals in different stages of in-
fection could be assisted in the same city, but at diverse sites.
Therefore, the site included in our study from Santos unfor-
tunately might have not been as representative as previously
expected.
The resistance assays currently in routine use detect resis-
tance only in the predominant viral population at the time
of testing. Therefore, when reversion to a wild-type variant
occurs, the transmitted mutations are no longer routinely
detectable.43 Thus, the rate of transmitted resistance observed
in this study may underestimate the true rates that could be
determined by resistance testing performed at the onset of
infection. Even if it is no longer detectable, transmitted drug-
resistant variants have been reported to persist in reservoirs
for many years after infection and may reappear under the
selective pressure exerted by antiretroviral therapy.44,45
Although our casuistic was significantly represented by
men who have sex with men (MSM; 43.2%), no particular risk
behavior population had higher levels of transmitted HIV
drug resistance, as the increased proportion of MSM among
persons carrying resistant viruses was not significant (Table
1). On the other hand, considering the reported increases in
sexually transmitted diseases among MSM,33,46,47 our results
may also indicate the need for improvement in the health care
system regarding prevention of further transmission of HIV in
this particular risk group.
Table 2. HIV Isolates with Antiretroviral Drug Resistance Found in the Study























16-18 B I84V T215D
06-20 B Y188L
06-21b B T69D
aSDRM (surveillance drug resistance mutations33).
bVirus with only one SDRM and no primary DRMs.
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We found a higher occurrence of transmitted drug resis-
tance in persons from the city of São Paulo, the capital of São
Paulo state, when compared to the rest of the country. This is
in agreement with the history of the HIV=AIDS epidemic in
Brazil, since São Paulo was among the first cities in Brazil
reporting AIDS cases, and remains the city with the highest
number of reported AIDS cases in the country.
In the present study, subjects reporting partners who took
ARV medications had a 2.5-fold risk of harboring HIV variants
with major drug resistance mutations, suggesting that these
viruses may have been transmitted directly from their partners
undergoing treatment. This finding implies that a proportion
of HIV-infected individuals receiving ARV medication is still
engaging in risk-related behavior, despite awareness of their
infection status.48 These patients are receiving medical atten-
tion, and healthcare providers should strongly consider them
as main targets for prevention programs.
The great majority of subjects harboring drug-resistant HIV
were infected with subtype B (91%) rather than with non-B
viruses (9%). This finding is in agreement with recent esti-
mates reported from southern Brazil, where a significant
proportion of subtype C ensures such comparison.49 Since
subtype B virus is the predominant subtype in Brazil,50 dif-
ferences in the prevalence of resistance according to virus
subtype may thus likely reflect the longer period during
which subtype B viruses have been exposed to antiretroviral
drugs. Alternatively, the fitness of subtype B viruses might be
less affected by the presence of transmitted drug resistance,
therefore allowing resistance mutations to persist for longer
times in that subtype. Large prospective cohorts infected with
distinct subtypes followed from acute infection will be nec-
essary to evaluate such alternatives.
We found a higher prevalence of mutations associated with
NNRTI resistance, which may reflect the extensive use of
NNRTI-based regimens compared with PI-based regimens.
Additionally, there may be a higher level of NNRTI resistance
in the general population, given that just one point mutation
can be sufficient to confer resistance to this class of drugs.51
Finally, NNRTI mutations have been shown to impact mod-
estly on viral fitness,52 and studies have found a high persis-
tence of these mutations in drug-naive subjects.53
In summary, viruses with resistance to at least one drug
were found in 5.7% of antiretroviral-naive patients in this
Brazilian cohort. Taking into account the important implica-
tions for treatment and prophylaxis of HIV infection, re-
sistance testing for mutations associated with reduced
susceptibility to ARV drugs (mainly when including an
NNRTI in HAART) might be considered prior to the initiation
of therapy, and should be considered in individuals who have
partners who are already on ARV therapy (who are at greater
risk of having drug resistance mutations).
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